John T - Search Results

1

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.

Arulananda S, O'Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, Walkiewicz M, O'Donoghue RJJ, Poh AR, Thapa B, Williams DS, Leong T, Mariadason JM, Li X, Cebon J, Lee EF, John T, Fairlie WD. Arulananda S, et al. Among authors: john t. Cell Death Discov. 2021 Jun 15;7(1):146. doi: 10.1038/s41420-020-00388-7. Cell Death Discov. 2021. PMID: 34131107 Free PMC article. No abstract available.

2

Immunotherapy of advanced or metastatic melanoma.

Cebon J, Gedye C, John T, Davis ID. Cebon J, et al. Among authors: john t. Clin Adv Hematol Oncol. 2007 Dec;5(12):994-1006. Clin Adv Hematol Oncol. 2007. PMID: 18277962 Review.

3

Predicting clinical outcome through molecular profiling in stage III melanoma.

John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS. John T, et al. Clin Cancer Res. 2008 Aug 15;14(16):5173-80. doi: 10.1158/1078-0432.CCR-07-4170. Clin Cancer Res. 2008. PMID: 18698035

4

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

Gedye C, Quirk J, Browning J, Svobodová S, John T, Sluka P, Dunbar PR, Corbeil D, Cebon J, Davis ID. Gedye C, et al. Among authors: john t. Cancer Immunol Immunother. 2009 Oct;58(10):1635-46. doi: 10.1007/s00262-009-0672-0. Epub 2009 Feb 17. Cancer Immunol Immunother. 2009. PMID: 19221743 Free PMC article.

5

Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer.

Sem Liew M, Arulananda S, Seow J, Mitchell P, John T. Sem Liew M, et al. Among authors: john t. J Thorac Oncol. 2011 Oct;6(10):1761-2. doi: 10.1097/JTO.0b013e318228a015. J Thorac Oncol. 2011. PMID: 21918391 Free article. No abstract available.

6

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T. Russell PA, et al. Among authors: john t. J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8. J Thorac Oncol. 2013. PMID: 23486266 Free article.

7

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS. John T, et al. PLoS One. 2013 Jul 23;8(7):e67876. doi: 10.1371/journal.pone.0067876. Print 2013. PLoS One. 2013. PMID: 23935846 Free PMC article.

8

Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

Wright GM, Do H, Weiss J, Alam NZ, Rathi V, Walkiewicz M, John T, Russell PA, Dobrovic A. Wright GM, et al. Among authors: john t. Oncotarget. 2014 Apr 30;5(8):2107-15. doi: 10.18632/oncotarget.1840. Oncotarget. 2014. PMID: 24742923 Free PMC article.

9

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, Mitchell P, Boutros P, John T. Ameratunga M, et al. Among authors: john t. PLoS One. 2016 Apr 22;11(4):e0153954. doi: 10.1371/journal.pone.0153954. eCollection 2016. PLoS One. 2016. PMID: 27104612 Free PMC article.

10

The ADAM Trial: Visiting the Road Less Traveled.

Arulananda S, John T. Arulananda S, et al. Among authors: john t. JAMA Oncol. 2017 Jan 1;3(1):66-67. doi: 10.1001/jamaoncol.2016.2854. JAMA Oncol. 2017. PMID: 27584157 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,409 results

Search Page